4.6 Article

Outcomes With Post-Dilation Following Transcatheter Aortic Valve Replacement

Journal

JACC-CARDIOVASCULAR INTERVENTIONS
Volume 7, Issue 7, Pages 781-789

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2014.02.013

Keywords

aortic stenosis; paravalvular regurgitation; post-dilation; prosthesis-patient mismatch; reballooning; transcatheter aortic valve replacement

Funding

  1. Philips Healthcare
  2. Edwards Lifesciences
  3. Boston Scientific Corporation
  4. AstraZeneca
  5. Bristol Myers Squibb
  6. Daiichi-Sankyo/Eli Lilly
  7. GlaxoSmithKline
  8. Janssen
  9. Merck/Schering-Plough
  10. Regeneron
  11. St. Jude Medical
  12. Abbott Vascular
  13. Medtronic
  14. Siemens
  15. Paieon
  16. Cordis
  17. MicroInterventional Devices
  18. Lantheus Medical Imaging
  19. GE Healthcare
  20. Boston Scientific

Ask authors/readers for more resources

Objectives This study sought to characterize the patients receiving post-implantation balloon dilation (PD) following transcatheter aortic valve replacement (TAVR) and evaluate procedural outcomes in the PARTNER (Placement of Aortic Transcatheter Valve) I trial. Background Following TAVR, PD has been used to treat paravalvular regurgitation. Methods The PARTNER I trial cohort A (n = 304) and cohort B (n = 194) patients randomized to TAVR and the nonrandomized continued access TAVR (n = 1,637) patients were included in the analysis. PD was performed at the discretion of the operator. Clinical events and echocardiographic variables were collected prospectively out to 1 year. Results The overall incidence of PD was 12.4%. PD patients had significantly less prosthesis-patient mismatch (p < 0.001) and larger effective orifice areas (p < 0.001) throughout the follow-up period. There were significantly more subacute strokes (occurring <7 days: 4.9% vs. 2.6%; p = 0.04) in PD patients but no difference in late stroke, either at 7 to 30 days (0.0% vs. 0.8%; p = 0.16) or >30 days (1.9 vs. 1.7%; p = 0.75). Although there was no significant increase in early mortality with PD, at 1 year, there was a trend for higher all-cause mortality (p = 0.054) and a significant difference in death or stroke (p = 0.04). When the subgroup of patients with none/trace paravalvular regurgitation were evaluated, there was no significant association of PD with mortality (p = 0.61) and death or stroke (p = 0.96). Multivariable analysis failed to show a relationship between PD and mortality. Conclusions PD is associated with reduced rates of moderate or severe prosthesis-patient mismatch with no evidence for short-term structural deterioration of the balloon-expandable transcatheter valve. Although PD is associated with a greater incidence of early stroke, there is no significant association between PD and stroke beyond 7 days. Multivariable analysis shows no significant association between PD and mortality. (J Am Coll Cardiol Intv 2014; 7: 781-9) (C) 2014 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available